Safety, Toleration and Pharmacokinetics of Single Intravenous Doses of Peptide YY in Overweight Adults

Pfizer

Status and phase: Completed; Phase 1

Conditions: Obesity

Treatments: Drug: Peptide YY3-36

Study type: Interventional

Funder types: Industry

Identifiers

NCT00331175

A9001292

Details and patient eligibility

About

The purpose of this trial is to evaluate the safety and tolerability of single escalating doses of Peptide YY3-36 and to determine effects on food intake and serum hormones when administered by intravenous infusion to otherwise healthy overweight adult subjects.

Sex: All

Ages: 18 to 55 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• BMI 27-35 kg/m2

Exclusion criteria

• Women of childbearing potential

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Single Blind